Search

Search Constraints

You searched for: Author/Creator Kofron, Ryan

Search Results

1. Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus–uninfected Individuals in HPTN 077. (24th May 2019)

2. Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. (19th March 2021)

3. Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. (18th March 2022)

4. HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention. (14th October 2022)

6. Low incidence and prevalence of hepatitis C in two cohorts of HIV pre‐exposure prophylaxis adherence interventions in men who have sex with men in Southern California. Issue 7 (12th April 2022)

7. Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. (15th December 2017)

8. Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States. (17th April 2021)

9. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Issue 7 (July 2020)